Xenon's Nav1.7 inhibitor misses in Phase II PHN trial

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) and partner Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) reported top-line data from a Phase II trial in 300 patients with postherpetic neuralgia (PHN) showing that twice-daily topical TV-45070 missed the primary endpoint of improving average daily pain scores from baseline to week 4 as measured by an 11-point numeric rating scale (NRS) vs. placebo. TV-45070 also missed the secondary endpoints of improving average NRS scores in the morning and evening, worst NRS score in the evening, percentage of patients with ≥30% and ≥50% improvements in weekly average NRS score, Neuropathic Pain Symptom Inventory (NPSI), Quality of Life Neuropathic Pain Impact on Quality of Life (NePIQoL), Patient Global Impression of Change (PGIC), Daily Sleep Interference Scale (DSIS), brush-evoked allodynia and punctate-evoked hyperalgesia vs. placebo...